


Data Sheet

Product Name:	GW0742
Cat. No.:	HY-13928
CAS No.:	317318-84-6
Molecular Formula:	C ₂₁ H ₁₇ F ₄ NO ₃ S ₂
Molecular Weight:	471.49
Target:	PPAR
Pathway:	Cell Cycle/DNA Damage; NF-κB
Solubility:	DMSO: ≥ 34 mg/mL



BIOLOGICAL ACTIVITY:

GW0742 (GW610742) is a potent and highly selective PPAR δ agonist. EC₅₀ values are 1nM, 1.1 μ M and 2 μ M for transactivation of human PPAR δ , - α , and - γ receptors respectively.

IC₅₀ value: 1nM, 1.1 μ M and 2 μ M (EC₅₀, for PPAR δ , - α , and - γ)

Target: PPAR

in vivo: GW0742 is a synthetic high affinity PPAR β/δ agonist, and its possible role in preventing the advance of inflammatory and apoptotic processes induced by bleomycin, that long-term leads to the appearance of pulmonary fibrosis. Our data showed that GW0742-treatment (0.3 mg/Kg, 10 percent DMSO, i.p.) has therapeutic effects on pulmonary damage, decreasing many inflammatory and apoptotic parameters detected by measurement of: 1) cytokine production; 2) leukocyte accumulation, indirectly measured as decrease of myeloperoxidase (MPO) activity; 3) I κ B α degradation and NF- κ B nuclear translocation; 4) ERK phosphorylation; 5) stress oxidative by NO formation due to iNOS expression; 6) nitrotyrosine and PAR localization; 7) the degree of apoptosis, evaluated by Bax and Bcl-2 balance, FAS ligand expression and TUNEL staining. Taken together, our results clearly show that GW0742 reduces the lung injury and inflammation due to the intratracheal BLEO—instillation in mice.[1]

References:

[1]. Galuppo M, et al. GW0742, a high affinity PPAR- β/δ agonist reduces lung inflammation induced by bleomycin instillation in mice. *Int J Immunopathol Pharmacol.* 2010 Oct-Dec;23(4):1033-46.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA